Ravuconazole (BioDeep_00000663607)
代谢物信息卡片
4-[2-[3-(2,4-Difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
化学式: C22H17F2N5OS (437.11218160000004)
中文名称: 立福康唑, 雷夫康唑
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O
InChI: InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-7-6-17(23)8-19(18)24/h2-8,10,12-14,30H,11H2,1H3
描述信息
C254 - Anti-Infective Agent > C514 - Antifungal Agent
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:143825
- KEGGdrug: D02556
- PubChem: 467825
- PubChem: 9845922
- DrugBank: DB06440
- ChEMBL: CHEMBL294029
- CAS: 194798-96-4
- CAS: 182760-06-1
- CAS: 170864-29-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Katsura Hata. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases.
Parasitology international.
2021 Apr; 81(?):102278. doi:
10.1016/j.parint.2020.102278. [PMID: 33370607] - Makoto Nakano, Yuto Aoki, Hideyo Yamaguchi. [Drug properties of fosravuconazole L-lysine ethanolate (NAILIN® Capsules 100 mg), a new oral azole therapeutic for onychomycosis: an analysis based on non-clinical and clinical trial data].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2019 ; 153(2):79-87. doi:
10.1254/fpj.153.79. [PMID: 30745518] - Sara Teixeira de Macedo Silva, Gonzalo Visbal, Joseane Lima Prado Godinho, Julio A Urbina, Wanderley de Souza, Juliany Cola Fernandes Rodrigues. In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis.
The Journal of antimicrobial chemotherapy.
2018 09; 73(9):2360-2373. doi:
10.1093/jac/dky229. [PMID: 29982734] - Fei Xie, Tingjunhong Ni, Jing Zhao, Lei Pang, Ran Li, Zhan Cai, Zichao Ding, Ting Wang, Shichong Yu, Yongsheng Jin, Dazhi Zhang, Yuanying Jiang. Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
Bioorganic & medicinal chemistry letters.
2017 05; 27(10):2171-2173. doi:
10.1016/j.bmcl.2017.03.062. [PMID: 28372907] - Pollyanna Álvaro Spósito, Ana Lia Mazzeti, Caroline de Oliveira Faria, Julio A Urbina, Gwenaelle Pound-Lana, Maria Terezinha Bahia, Vanessa Furtado Mosqueira. Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.
International journal of nanomedicine.
2017; 12(?):3785-3799. doi:
10.2147/ijn.s133708. [PMID: 28553114] - Natalia Mast, Joseph B Lin, Irina A Pikuleva. Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.
Molecular pharmacology.
2015 Sep; 88(3):428-36. doi:
10.1124/mol.115.099598. [PMID: 26082378] - Sarah Abdalla Ahmed, Wendy Kloezen, Frederick Duncanson, Ed E Zijlstra, G Sybren de Hoog, Ahmed H Fahal, Wendy W J van de Sande. Madurella mycetomatis is highly susceptible to ravuconazole.
PLoS neglected tropical diseases.
2014 Jun; 8(6):e2942. doi:
10.1371/journal.pntd.0002942. [PMID: 24945848] - Sheng-zheng Wang, Chun-quan Sheng, Wan-nian Zhang. [Recent advances in the study of new antifungal lead compounds].
Yao xue xue bao = Acta pharmaceutica Sinica.
2010 Aug; 45(8):966-75. doi:
". [PMID: 21351583] - Jay O Knipe, Kathleen W Mosure. Nonclinical pharmacokinetics of BMS-292655, a water-soluble prodrug of the antifungal ravuconazole.
Biopharmaceutics & drug disposition.
2008 Jul; 29(5):270-9. doi:
10.1002/bdd.612. [PMID: 18548464] - Jing-He Yan, Maria R Marino, Robert A Smith, Vanaja Kanamaluru, Edward M O'Mara, Dennis M Grasela. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.
Journal of clinical pharmacology.
2006 Feb; 46(2):193-200. doi:
10.1177/0091270005283462. [PMID: 16432271] - Andreas H Groll, Diana Mickiene, Vidmantas Petraitis, Ruta Petraitiene, Amy Kelaher, Alia Sarafandi, Gudrun Wuerthwein, John Bacher, Thomas J Walsh. Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
The Journal of antimicrobial chemotherapy.
2005 Nov; 56(5):899-907. doi:
10.1093/jac/dki287. [PMID: 16172108] - A K Gupta, C Leonardi, R R Stoltz, P F Pierce, B Conetta. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2005 Jul; 19(4):437-43. doi:
10.1111/j.1468-3083.2005.01212.x. [PMID: 15987289] - William J Steinbach. Antifungal agents in children.
Pediatric clinics of North America.
2005 Jun; 52(3):895-915, viii. doi:
10.1016/j.pcl.2005.02.009. [PMID: 15925667] - Li-Ping Zhu, Cristina Gil-Lamaignere, Frank-Michael C Müller. Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.
Mycoses.
2004 Aug; 47(7):319-25. doi:
10.1111/j.1439-0507.2004.00998.x. [PMID: 15310338] - Ruta Petraitiene, Vidmantas Petraitis, Caron A Lyman, Andreas H Groll, Diana Mickiene, Joanne Peter, John Bacher, Kristin Roussillon, Melissa Hemmings, Derrek Armstrong, Nilo A Avila, Thomas J Walsh. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Antimicrobial agents and chemotherapy.
2004 Apr; 48(4):1188-96. doi:
10.1128/aac.48.4.1188-1196.2004. [PMID: 15047519] - Vidmantas Petraitis, Ruta Petraitiene, Alia A Sarafandi, Amy M Kelaher, Caron A Lyman, Heather E Casler, Tin Sein, Andreas H Groll, John Bacher, Nilo A Avila, Thomas J Walsh. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
The Journal of infectious diseases.
2003 Jun; 187(12):1834-43. doi:
10.1086/375420. [PMID: 12792859] - D Andes, K Marchillo, T Stamstad, R Conklin. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.
Antimicrobial agents and chemotherapy.
2003 Apr; 47(4):1193-9. doi:
10.1128/aac.47.4.1193-1199.2003. [PMID: 12654646] - Jun Ohwada, Chikako Murasaki, Toshikazu Yamazaki, Shigeyasu Ichihara, Isao Umeda, Nobuo Shimma. Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
Bioorganic & medicinal chemistry letters.
2002 Oct; 12(19):2775-80. doi:
10.1016/s0960-894x(02)00557-7. [PMID: 12217374] - Hiroshiege Mikamo, Xiang Hua Yin, Yoh Hayasaki, Yoshiko Shimamura, Keizo Uesugi, Nobuyuki Fukayama, Masaru Satoh, Teruhiko Tamaya. Penetration of ravuconazole, a new triazole antifungal, into rat tissues.
Chemotherapy.
2002 Mar; 48(1):7-9. doi:
10.1159/000048580. [PMID: 11901249] - William R Kirkpatrick, Sofia Perea, Brent J Coco, Thomas F Patterson. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.
The Journal of antimicrobial chemotherapy.
2002 Feb; 49(2):353-7. doi:
10.1093/jac/49.2.353. [PMID: 11815579] - J Roberts, K Schock, S Marino, V T Andriole. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.
Antimicrobial agents and chemotherapy.
2000 Dec; 44(12):3381-8. doi:
10.1128/aac.44.12.3381-3388.2000. [PMID: 11083644] - J Bartroli, E Turmo, M Algueró, E Boncompte, M L Vericat, L Conte, J Ramis, M Merlos, J García-Rafanell, J Forn. New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol.
Journal of medicinal chemistry.
1998 May; 41(11):1855-68. doi:
10.1021/jm970726e. [PMID: 9599236] - K Hata, J Kimura, H Miki, T Toyosawa, T Nakamura, K Katsu. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Antimicrobial agents and chemotherapy.
1996 Oct; 40(10):2237-42. doi:
10.1128/aac.40.10.2237. [PMID: 8891121]